Plasma Level’s of Neuregulin-1 in Healthy People
Open Access
- 12 January 2022
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (6), 853-859
- https://doi.org/10.20996/1819-6446-2021-11-01
Abstract
Aim. To determine the median levels of neuregulin-1 (NRG-1; endothelium-derived growth factor and the natural agonist of the ERBB3 and ERBB4 receptors) NRG-1 in healthy volunteers and to study the associations of NRG-1 levels with gender and age. Material and Methods. Ninety seven healthy participants were enrolled (median age of 44 [32-54], men 45 men [46.4%]). The following age groups were identified: 20-29 y.о. (n=20, men – 50.0%), 30-39 y.о. (n=21, men – 52.4%), 40-49 y.о. (n=22, men – 45.5%), 50-59 y.о. (n=22, men – 36.4%); 60-69 y.о. (n=12, men – 50.0%). Peripheral blood samples were collected at the time of enrolment, standard laboratory tests were performed, and NRG-1 levels were determined in the plasma samples by ELISA. Results. In the cohort of 97 healthy participants the median value of NRG-1 was 0.3 [0.121-2.24] ng/ml. NRG-1 levels did not differ significantly between men and women (p=0.145), indicating that NRG-1 levels are not influenced by gender. The levels of NRG-1 were similar in the different age groups: age 20-29 years=0.26 [0.17-0.37] ng/ml; age 30-39=0.24 [0.1-0.39] ng/ml; age 40-49=0.31 [0.19-1.15] ng/ml; age 50-59=0.37 [0.19-1.0] ng/ml; age 60-69=0.4 [0.13-0.81] ng/ml. Correlation analysis between NRG-1 levels and route blood measurements (haemoglobin, lipids, glucose, creatinine, and uretic acid) did not show significant associations. Conclusions. In this study, the median value of NRG-1 plasma levels were determined. The results of the study show that age and gender had no influence on NRG-1 values.Keywords
This publication has 21 references indexed in Scilit:
- Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemiaCoronary Artery Disease, 2011
- Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphismJournal of Neural Transmission, 2010
- A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart FailureJournal of Invasive Cardiology, 2010
- Neuregulin-1β Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart FailureJournal of the American College of Cardiology, 2009
- Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart InjuryCell, 2009
- The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talkOnline Journal of Public Health Informatics, 2006
- The ERBB4/HER4 Intracellular Domain 4ICD Is a BH3-Only Protein Promoting Apoptosis of Breast Cancer CellsCancer Research, 2006
- Dilated cardiomyopathy in Erb-b4-deficient ventricular muscleAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expressionNeurobiology of Disease, 2005